atai Life Sciences

Historical price data

atai Life Sciences aims to transform mental health treatment by leveraging a decentralized platform to accelerate the development of psychedelic-inspired therapeutics. The company's strategy involves identifying, incubating, and advancing a diverse pipeline of drug candidates, primarily targeting treatment-resistant depression and other high-need conditions. As a public company, atai has raised significant capital to fund its clinical programs and has established collaborations with leading scientific institutions. Its approach combines novel compounds with digital therapeutics and data analytics to address the global mental health crisis.

A decentralized biotech platform that identifies, acquires, and incubates multiple drug development programs, providing centralized expertise in R&D, regulatory strategy, data science, and capital allocation.

Total raised: $579.2M

Competes directly with other psychedelic biotechs (COMPASS Pathways, MindMed, Cybin) and indirectly with large pharma (J&J) in the rapid-acting antidepressant space. Differentiation is sought through a diversified portfolio approach, proprietary chemical entities, and an integrated digital strategy, but the field is becoming increasingly crowded.